Health Canada temporarily authorized the adjunctive use of the Dexcom G6 Continuous Glucose Monitoring (CGM) system during COVID-19 by pregnant women with Type 1, Type 2, or gestational diabetes to compliment the use of blood glucose meters until March 18, 2021, unless the authorization requires changes within that timeframe.  For more information, please review the formal update on the Health Canada Website.